Maitake and Reduced Chemoradiotherapy-Related Adverse Event

• Effect of Maitake D-fraction in advanced laryngeal and pharyngeal cancers during concurrent chemoradiotherapy: A randomized clinical trial.

  • 2022-09-01
  • RCT · n = 141
  • Acta biochimica Polonica 69(3)
  • • Qinglei Hu
    • Binli Xie

  • PubMed: 36070433
  • DOI: 10.18388/abp.2020_5996

  3 Insights on

  • Reduced Chemoradiotherapy-Related Adverse Event

  • High evidence
  • Large Human Trial
  • Clinical

  Frequencies of severe CCRT-associated adverse events in intervention group were less than in placebo group.

  Effect

  Beneficial

  Effect size

  Moderate

  Significant

  Yes

  Dose

  4 capsules 3 times a day